| Market Cap | 218.91M | P/E | - | EPS this Y | 18.70% | Ern Qtrly Grth | - |
| Income | -46.34M | Forward P/E | -4.60 | EPS next Y | 86.50% | 50D Avg Chg | -9.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -2.00% |
| Dividend | N/A | Price/Book | 3.42 | EPS next 5Y | - | 52W High Chg | -48.00% |
| Recommedations | 2.00 | Quick Ratio | 6.67 | Shares Outstanding | 54.98M | 52W Low Chg | 53.00% |
| Insider Own | 1.01% | ROA | -42.47% | Shares Float | 54.43M | Beta | 1.89 |
| Inst Own | 34.18% | ROE | -74.02% | Shares Shorted/Prior | 9.38M/7.77M | Price | 4.14 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 748,320 | Target Price | 13.00 |
| Oper. Margin | - | Earnings Date | May 13 | Volume | 548,683 | Change | -3.50% |
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
| JMP Securities | Market Outperform | Apr 9, 24 |
| Needham | Buy | Apr 9, 24 |
| RBC Capital | Outperform | Mar 13, 24 |
| Needham | Buy | Mar 12, 24 |
| Truist Securities | Buy | Jan 31, 24 |
| Needham | Buy | Nov 15, 23 |
| RBC Capital | Outperform | Nov 15, 23 |
| Truist Securities | Buy | Nov 15, 23 |
| JMP Securities | Market Outperform | Nov 15, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Costa Paulo F | Director Director | May 17 | Buy | 4.65 | 10,000 | 46,500 | 10,000 | 05/18/23 |
| Stewart Robert A | Director Director | May 17 | Buy | 4.3735 | 10,000 | 43,735 | 11,000 | 05/18/23 |
| Todisco Joseph | Chief Executive Offi.. Chief Executive Officer | May 17 | Buy | 4.58 | 5,000 | 22,900 | 209,726 | 05/18/23 |
| Todisco Joseph | Chief Executive Offi.. Chief Executive Officer | Nov 15 | Buy | 3.82 | 20,000 | 76,400 | 242,169 | 11/16/22 |
| Todisco Joseph | Chief Executive Offi.. Chief Executive Officer | Aug 24 | Buy | 3.9200 | 4,700 | 18,424 | 222,169 | 08/25/22 |
| Kaplan Myron | Director Director | May 17 | Buy | 3.78 | 5,000 | 18,900 | 160,034 | 05/18/22 |
| Todisco Joseph | Chief Executive Offi.. Chief Executive Officer | May 16 | Buy | 3.3800 | 10,000 | 33,800 | 217,469 | 05/17/22 |